Peptide News Digest

Marea MAR002 First-in-Class Anti-GHR Antibody Phase 1 at ENDO 2026, EMA Synthetic Peptide Guideline Effective, Pep2Tango PTT-A Tetra-Agonist Beats Tirzepatide, France Wegovy/Mounjaro Reimbursement Live, BU Sontha 60K-Patient GLP-1 Discontinuation Study, Italgel + GELITA Collagen Peptide Launches

Marea MAR002 anti-GHR Phase 1 at ENDO 2026, EMA synthetic peptide guideline effective, Pep2Tango PTT-A 19%, France Wegovy reimbursement, Sontha 60K GLP-1 data.

10 stories · Covering clinical-trials, regulatory, research, industry

Editor's Note

Friday closes out the ENDO 2026 cycle with Marea Therapeutics releasing first-in-human Phase 1 data on MAR002, an allosteric human monoclonal antibody to the growth hormone receptor that targets infrequent subcutaneous dosing as a fundamental rewrite of pegvisomant-style acromegaly therapy. The same Pharma Friday roundup carried Recordati's ISTURISA LINC-program data on Cushing's syndrome biochemical control and patient-reported outcomes, extending the small-molecule corticosteroid-synthesis-inhibitor side of the rare endocrine slate. Boston University's Sainikhil Sontha presented a 60,000-patient real-world claims analysis showing 40% of T2D patients discontinue GLP-1s within 12 months and 41.5% restart within a year, with tirzepatide users 41% less likely to discontinue than liraglutide. On the regulatory side, the EMA's first-ever dedicated synthetic peptide guideline (EMA/CHMP/CVMP/QWP/367182/2025) became legally effective June 1 with reach across human and veterinary peptide APIs, and France joined the UK and Switzerland by extending public insurance coverage to Wegovy and Mounjaro effective June 15 at 65% reimbursement. In the post-ADA 'moving beyond GLP-1' arc, Pep2Tango Therapeutics' PTT-A tetra-agonist hitting GLP-1, GIP, amylin, and calcitonin receptors produced 19% weight loss in DIO rats versus 12% for tirzepatide and CagriSema with preserved muscle mass. Cosmetic peptides crossed two distinct industry milestones in the past week: Italgel's avvera collagen peptide launched June 12 backed by a 67-women RCT versus a comparator collagen, and GELITA's Bioactive Collagen Peptide CURADERM premiered at Vitafoods Europe 2026 for skin barrier and oral health. Lexaria Bioscience completed its DehydraTECH oral retatrutide and amycretin animal study, and the Peptide World Congress 2026 opens in Arizona today through Saturday for the clinical-peptide-prescriber community.

Clinical Trials

Marea Therapeutics MAR002 Phase 1 First-in-Human Data at ENDO 2026: First Allosteric Anti-GHR Monoclonal Antibody Targets Bi-Weekly Acromegaly Dosing vs Daily Pegvisomant

Marea Therapeutics (Endocrine News Pharma Friday, June 19) released Phase 1 first-in-human data for MAR002, a first-in-class half-life-extended allosteric human monoclonal antibody growth hormone receptor antagonist (GHRA), at ENDO 2026 in Chicago. The Phase 1 readout supports a potential best-in-disease profile across safety, tolerability, pharmacodynamic IGF-1 lowering, and pharmacokinetics, with a long duration of action compatible with infrequent subcutaneous dosing — potentially once every two weeks — versus the daily subcutaneous administration required for pegvisomant (Somavert). MAR002 sits at the intersection of acromegaly's existing somatostatin (octreotide, lanreotide, Palsonify), GH-receptor (pegvisomant), and dopamine agonist (cabergoline) approaches and reframes the GHR antagonist class around an antibody, not a pegylated protein. Acromegaly's US/EU prevalence is roughly 40-70 per million.

#marea-therapeutics #mar002 #acromegaly #growth-hormone-receptor #monoclonal-antibody #endo-2026
Regulatory

EMA Synthetic Peptide Guideline (EMA/CHMP/CVMP/QWP/367182/2025) Comes Into Force June 1, 2026: First-Ever EU-Wide Quality, Manufacturing, and Impurity Standard for All Synthetic Peptide APIs

The European Medicines Agency's first-ever dedicated 'Guideline on the Development and Manufacture of Synthetic Peptides' (EMA/CHMP/CVMP/QWP/367182/2025) entered into force June 1, 2026 after adoption by CHMP on December 1, 2025 and CVMP on December 4, 2025. The guideline applies to both new and existing synthetic peptide active substances used in human and veterinary medicines, including investigational medicinal products and post-authorisation changes, and covers manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, comparability requirements, characterization, specifications, and analytical control. Biological peptides produced by recombinant technology and radiopharmaceuticals are excluded. The standard arrives on the same regulatory calendar as the FDA's PCAC peptide reclassification review (July 23-24, 2026) and the FDA's 503B GLP-1 bulks exclusion comment window (closes June 29).

#ema #synthetic-peptides #manufacturing #quality-guideline #eu-regulation
Research

Pep2Tango PTT-A Tetra-Agonist (GLP-1 + GIP + Amylin + Calcitonin) Produces 19% Weight Loss in DIO Rats vs 12% for Tirzepatide and CagriSema With Muscle Preservation

Pep2Tango Therapeutics presented preclinical data on PTT-A, a novel long-acting unimolecular peptide tetra-agonist activating the GLP-1, GIP, amylin, and calcitonin receptors simultaneously, in a Medscape 'Moving Beyond GLP-1s' feature drawing from the ADA 2026 session 'Novel Strategies for Obesity Pharmacology' (oral abstracts 85-OR and 299-OR, Diabetes journal supplement). In 21-day chronic studies in diet-induced obese rats, the higher PTT-A dose achieved 19% body weight reduction versus the vehicle, compared to 12% each for tirzepatide and cagrilintide + semaglutide (CagriSema). Body composition analysis showed fat-mass loss without lean-mass loss, distinguishing PTT-A's profile from tirzepatide's documented muscle-loss pattern. PTT-A also showed robust glucose lowering, plasma lipid improvement, insulin sensitization, and liver-fat benefits.

#pep2tango #ptt-a #tetra-agonist #amylin #calcitonin #obesity #muscle-preservation #ada-2026
Research

Boston University ENDO 2026 (Sontha): 60,000-Patient Claims Analysis Shows 40% of T2D Patients Stop GLP-1 Within 12 Months, 41.5% Restart Within a Year — Tirzepatide Users 41% Less Likely to Discontinue Than Liraglutide

An analysis of 60,000+ Americans with type 2 diabetes, presented at ENDO 2026 by Sainikhil Sontha (Boston University School of Public Health) and published in the Endocrine Society press release stream, found that 40% of GLP-1 users discontinued the medication within 12 months and roughly 60% had stopped by the end of two years. Among those who stopped, 41.5% restarted within a year and 58% within two years. Discontinuation was higher among Medicaid/Medicare beneficiaries, Black patients, and patients with documented nausea or GI side effects (37% of stoppers). Newer-generation tirzepatide users were 41% less likely to discontinue than liraglutide users, and patients whose first GLP-1 was prescribed by an endocrinologist were 10% less likely to stop. The data complement the Cleveland Clinic 8,000-patient real-world finding (March) and the eClinicalMedicine Budini meta-regression on weight-regain trajectory, sharpening the picture of how GLP-1 therapy churn actually unfolds in US insurance-claims populations.

#glp-1-discontinuation #glp-1-reinitiation #endo-2026 #boston-university #tirzepatide #liraglutide #real-world-evidence
Regulatory

France Joins UK and Switzerland: Wegovy (Semaglutide) and Mounjaro (Tirzepatide) Public Insurance Coverage Live June 15 With 65% Sécurité Sociale Reimbursement

Wegovy and Mounjaro became reimbursable by French Health Insurance effective June 15, 2026 under orders published in the May 28, 2026 Journal Officiel. The patient co-payment rate is 35%, leaving 65% public coverage by the Sécurité Sociale. Eligibility is restricted to specific patient profiles: adults with BMI ≥30 plus a major obesity-associated comorbidity (Wegovy) or with type 2 diabetes (Mounjaro). The decision follows the UK and Switzerland in extending public insurance to GLP-1 obesity therapy, and marks a paradigm shift from 'personal responsibility' toward 'treatable disease' framing in continental European health systems. The change comes ahead of EMA Wegovy pill (oral semaglutide 25 mg) EU launches in H2 2026 following the May 22 CHMP positive opinion.

#france #wegovy #mounjaro #semaglutide #tirzepatide #public-reimbursement #european-health-policy
Industry

Italgel Launches Avvera Collagen Peptide June 12, 2026 With Bionos Biotech RCT in 67 Women: Faster Crow's-Feet Reduction at Day 28 vs Comparator Collagen at 2.5 g/Day

Italian producer Italgel launched avvera, a 'next-generation collagen for skin beauty,' on June 12, 2026 backed by a published double-blind parallel-group eight-week study conducted by Bionos Biotech S.L. in Spain. The randomized trial enrolled 67 healthy women aged 38-66 who received 2.5 g/day of either avvera or an established comparator collagen. Avvera showed greater reductions in crow's-feet wrinkle area and length at day 28, though between-group differences narrowed by day 56. Skin hydration improved 43.5% versus 42.9% for the active control at day 56. Italgel attributes the faster onset to its trademarked 'High-Dration System' production technology, which increases water storage in the skin while reducing transepidermal water loss via improved epidermal barrier function. The launch enters the cosmetic-peptide market alongside GELITA's CURADERM at Vitafoods Europe.

#italgel #avvera #collagen-peptide #cosmetic-peptides #skin-health #bionos-biotech
Industry

GELITA Debuts as Official Collagen Sponsor at Vitafoods Europe 2026 With Bioactive Collagen Peptide CURADERM for Skin Barrier and Gum Health

Collagen specialist GELITA debuted as the official collagen sponsor at Vitafoods Europe 2026, launching its new Bioactive Collagen Peptide CURADERM for skin barrier integrity and oral/gum health applications. CURADERM joins GELITA's collagen-peptide product family alongside VERISOL (skin elasticity and anti-wrinkle), BODYBALANCE (muscle and body composition), TENDOFORTE (tendon and ligament), and FORTIGEL (joint cartilage). The launch underscores the cosmetic and functional peptide market's continued bifurcation between branded bioactive collagen peptides (with claim-supporting clinical data) and commodity collagen powders. BASF earlier launched NeoHelix Regenerate and SkinNexus Collag3n at in-cosmetics Global Paris in April, completing a strong 2026 cycle of cosmetic-peptide industry launches just as the wellness market navigates the FDA July PCAC peptide-reclassification decision.

#gelita #curaderm #bioactive-collagen-peptide #vitafoods-europe-2026 #cosmetic-peptides #skin-health
Industry

Lexaria Bioscience Completes DehydraTECH Animal Study #2 (GLP-1-A26-2) on Retatrutide and Amycretin June 9: Targeting Oral Formulation Enhancements and IP Claims on Next-Generation GLP-1s

Lexaria Bioscience (NASDAQ: LEXX) announced June 9, 2026 that dosing has been completed in Animal Study #2 (GLP-1-A26-2) evaluating its DehydraTECH oral peptide delivery platform with two next-generation GLP-1 drugs: Eli Lilly's retatrutide (triple GIP/GLP-1/glucagon agonist) and Novo Nordisk's amycretin (unimolecular GLP-1/amylin agonist). The study tested formulation enhancements designed to improve DehydraTECH performance and stake intellectual property claims on next-generation oral GLP-1 delivery. The data follows Lexaria's April 23 study launch and feeds the broader oral GLP-1 platform competition with Novo Nordisk's Wegovy pill (3M US prescriptions in 5 months) and Lilly's orforglipron (Foundayo, approved April 2026). Lexaria's industry update June 17 framed the oral GLP-1 pill segment as 'billions in new industry sales' potential.

#lexaria-bioscience #dehydratech #oral-glp-1 #retatrutide #amycretin #drug-delivery
Clinical Trials

Recordati ISTURISA (Osilodrostat) LINC Program ENDO 2026 Data: Four Cushing's Syndrome Poster Presentations on Biochemical Control, Patient-Reported Quality of Life, and Real-World Outcomes

Recordati Rare Diseases presented four poster analyses at ENDO 2026 from the LINC clinical program for ISTURISA (osilodrostat), the oral 11β-hydroxylase inhibitor approved for Cushing's syndrome. The posters covered patient-reported quality-of-life improvements, biochemical control durability, real-world treatment outcomes across LINC 3 and LINC 4 study extensions, and clinical responses across the heterogeneous Cushing's syndrome population. ISTURISA was approved in March 2020 for Cushing's disease and expanded to broader Cushing's syndrome in April 2025; the LINC 3 pivotal study showed 86% of patients normalized urinary free cortisol after eight weeks of randomized withdrawal versus 29% with placebo. Endogenous Cushing's syndrome remains an ultra-rare endocrine disorder with limited therapeutic alternatives (ketoconazole, metyrapone, mifepristone, pasireotide).

#recordati #isturisa #osilodrostat #cushing-syndrome #linc-program #endo-2026
Industry

Peptide World Congress 2026 Opens June 19-20 at Arizona Biltmore: Practitioner-Facing Annual Conference for Clinical Peptide Therapy on the Eve of FDA July PCAC Review

Peptide World Congress 2026 opens today (June 19-20, 2026) at Arizona Biltmore, LXR Hotels & Resorts in Phoenix, bringing together the clinical-peptide-prescriber community for two days of practitioner-focused sessions on therapeutic peptide protocols, dosing, indications, and case-based clinical reasoning. The agenda spans cellular aging, regenerative protocols, and clinical applications across orthopedic, metabolic, immune, and longevity indications. The conference falls roughly five weeks ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee meeting, which will determine whether BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin, and the other Category-2-reclassified peptides advance toward 503A compounding-list eligibility. The community-conference format reflects how rapidly clinical peptide prescribing has moved from off-label specialty practice to a formal CME-adjacent ecosystem.

#peptide-world-congress #clinical-peptide-prescribing #ssrp-institute #pcac-meeting #professional-conference